introduced the developmentally regulated tight junction protein claudin 6 (CLDN6) as a CAR target in solid tumors and demonstrated that CAR-T cell-amplifying RNA vaccine was a suitable approach in treating with CLDN6+ lung tumors, without cytokine release syndrome (CRS) (84). The gene discussed is CLDN6; the disease is congenital rubella syndrome.